Waters Corporation Working Capital

Working Capital of WAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending December 30, 2020 was $596 Million (a 4.66% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -23.26%
  • Annual Working Capital for 2020 was $596 Million (a -17.35% decrease from previous year)
  • Annual Working Capital for 2019 was $721 Million (a -67.43% decrease from previous year)
  • Annual Working Capital for 2018 was $2.21 Billion (a -39.57% decrease from previous year)
Visit stockrow.com/WAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of Waters Corporation

Most recent Working Capitalof WAT including historical data for past 10 years.

Interactive Chart of Working Capital of Waters Corporation

Waters Corporation Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $596.05 $569.49 $572.11 $776.73 $596.05
2019 $721.16 $746.75 $1,008.71 $1,474.51 $721.16
2018 $2,214.23 $2,522.64 $2,649.08 $2,904.23 $2,214.23
2017 $3,663.98 $3,416.38 $3,293.95 $3,146.21 $3,663.98
2016 $3,115.12 $3,014.87 $2,883.33 $2,786.59 $3,115.12
2015 $2,649.46 $2,557.89 $2,460.26 $2,337.5 $2,649.46
2014 $2,236.56 $2,124.93 $2,086.02 $2,023.26 $2,236.56
2013 $2,068.72 $1,936.18 $1,869.33 $1,810.82 $2,068.72
2012 $1,753.48 $1,369.94 $1,343.64 $1,375.2 $1,753.48
2011 $1,340.24 $1,257.78 $1,332.71 $967.11 $1,340.24
2010 $1,200.79 $1,020.92 $949.29 $1,200.79

Business Profile of Waters Corporation

Sector: Healthcare
Industry: Diagnostics & Research
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.